The Newsroom
Policy·October 20, 2026 at 12:47 PM EDT·1 source

STAT+: A bipartisan group of lawmakers urges the FDA to close a peptide loophole

LLY -2.5%
LLY · last 30 trading days+2.7% since the news
News

What happened

  • A bipartisan group of lawmakers urged the FDA to close a loophole used to import knockoff retatrutide.
  • Retatrutide is an investigational obesity drug made by Eli Lilly.

Why it matters

The request could affect FDA oversight and the availability of unapproved peptide products, with implications for healthcare companies and regulatory professionals.

What to watch. FDA action on the lawmakers’ request.

Read more on YouBank

The Newsroom, ranked for your desk

About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.

Timeline

  1. EarlierOct 19
    Here are Monday's biggest analyst calls: SpaceX, Nvidia, Apple, CoreWeave, Amazon, Meta, Eli Lilly & more
  2. EarlierOct 19
    EyePoint's Phase 3 failure; Lilly's China drug delivery deal
  3. First reported by STATOct 20
    STAT+: A bipartisan group of lawmakers urges the FDA to close a peptide loophole

Who is involved

STAT+: A bipartisan group of lawmakers urges the FDA to close…FDAEli LillyLLY
AgencyCompany

Sources (1)

  1. STATOct 20
    STAT+: A bipartisan group of lawmakers urges the FDA to close a peptide loophole

Related

Read more on YouBank

The Newsroom, ranked for your desk

About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.

  • Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
  • Follow developing storiesAn alert, and a push, the moment a story you follow moves.
  • Your briefing, read aloudA few minutes each morning with a chapter per story.
  • Brief modeSwipe through the day, a 20-second card each.